Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes
Xavier Leleu, Thomas G. Martin, Katja Weisel, et al.
Annals of Hematology (2022) Vol. 101, Iss. 10, pp. 2123-2137
Open Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
Xavier Leleu, Cyrille Hulin, Jérôme Lambert, et al.
Nature Medicine (2024) Vol. 30, Iss. 8, pp. 2235-2241
Open Access | Times Cited: 27
NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma
Christie P.M. Verkleij, Kristine A. Frerichs, Marloes E.C. Broekmans, et al.
HemaSphere (2023) Vol. 7, Iss. 5, pp. e881-e881
Open Access | Times Cited: 22
Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma
Kamlesh Bisht, Taro Fukao, Marielle Chiron, et al.
Cancer Medicine (2023) Vol. 12, Iss. 20, pp. 20332-20352
Open Access | Times Cited: 20
Communication between bone marrow mesenchymal stem cells and multiple myeloma cells: Impact on disease progression
Daniel García‐Sánchez, Alberto González-González, Ana Alfonso-Fernández, et al.
World Journal of Stem Cells (2023) Vol. 15, Iss. 5, pp. 421-437
Open Access | Times Cited: 17
CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond
Abhinava K. Mishra, Ashna Gupta, Gunjan Dagar, et al.
Vaccines (2023) Vol. 11, Iss. 11, pp. 1721-1721
Open Access | Times Cited: 16
An NAD+-dependent metabolic checkpoint regulates hematopoietic stem cell activation and aging
Zehan Song, Sang Hee Park, Wei‐Chieh Mu, et al.
Nature Aging (2024) Vol. 4, Iss. 10, pp. 1384-1393
Closed Access | Times Cited: 7
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature
Emiliano Barbieri, Enrica Antonia Martino, Elena Rivolti, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 5, pp. 365-381
Closed Access | Times Cited: 6
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA
Evangelos Terpos, Ioannis Ntanasis‐Stathopoulos, Maria Gavriatopoulou, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 3, pp. 396-407
Open Access | Times Cited: 5
Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma
Paola Tacchetti, Simona Barbato, Katia Mancuso, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2337-2337
Open Access | Times Cited: 5
Long-Term Effectiveness and Safety of Isatuximab in Combination with Pomalidomide and Dexamethasone in a Japanese Patient with Refractory Multiple Myeloma and 1q21 Amplification: A Case Report
Takanori Yoshioka, Yasuhisa Sando, Kazutaka Sunami
Case Reports in Oncology (2025), pp. 1-14
Open Access
Efficacy and safety of anti-CD38 monoclonal antibodies-based therapy versus standard therapy in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis
Muhammad Osama, Muhammad Haris Khan, Sharib Raza Khan, et al.
Therapeutic Advances in Hematology (2025) Vol. 16
Open Access
Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects
Alberto L. Horenstein, Angelo Corso Faini, Fabio Morandi, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
CD99 tumor associated antigen is a potential target for antibody therapy of T-cell acute lymphoblastic leukemia
Kamonporn Kotemul, Watchara Kasinrerk, Nuchjira Takheaw
Exploration of Targeted Anti-tumor Therapy (2024) Vol. 5, Iss. 1, pp. 96-107
Open Access | Times Cited: 4
Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long‐term outcomes in the Phase 3 IKEMA study
Thierry Façon, Philippe Moreau, Ivan Špıčka, et al.
Hematological Oncology (2024) Vol. 42, Iss. 2
Open Access | Times Cited: 4
Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature review
Francesca Gay, Elena Zamagni, Craig E. Cole, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis
Thierry Façon, Philippe Moreau, Ross Baker, et al.
Haematologica (2023) Vol. 109, Iss. 2, pp. 604-616
Open Access | Times Cited: 10
Subsequent therapy and outcomes in patients with newly diagnosed multiple myeloma experiencing disease progression after quadruplet combinations
Gayathri Ravi, Susan Bal, Laura Joiner, et al.
British Journal of Haematology (2024) Vol. 204, Iss. 4, pp. 1300-1306
Open Access | Times Cited: 3
Isatuximab-Specific Immunofixation Electrophoresis Assay to Remove Interference in Serum M-Protein Measurement in Patients with Multiple Myeloma
Katie Thoren, Samia Menad, Georges Nouadje, et al.
The Journal of Applied Laboratory Medicine (2024) Vol. 9, Iss. 4, pp. 661-671
Open Access | Times Cited: 3
Exploring the depths of IgG4: insights into autoimmunity and novel treatments
Selen Ünlü, Blanca G. Sánchez Navarro, Elif Çakan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Anti-HLA serological response to CD38-targeting desensitization therapy is challenged by peripheral memory B-cells in highly sensitized kidney transplant candidates
Alba Torija, Matignon Marie, V. Loures Flávio, et al.
American Journal of Transplantation (2024)
Closed Access | Times Cited: 3
Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future
H. N. Abramson
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 21, pp. 15674-15674
Open Access | Times Cited: 8
c‐FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myeloma
Naoki Osada, Jiro Kikuchi, Hidekatsu Iha, et al.
Clinical and Translational Medicine (2023) Vol. 13, Iss. 8
Open Access | Times Cited: 7
Clinical outcomes of pomalidomide‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China
Xiaoyan Han, Xincheng Jiang, Jingsong He, et al.
Cancer Medicine (2024) Vol. 13, Iss. 9
Open Access | Times Cited: 2
Preclinical characterization of a novel investigational monoclonal antibody CM313 with potent CD38-positive cell killing activity
Wei Liu, Juntao Yu, Kaiwen Sun, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future
H. N. Abramson
(2023)
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top